Abstract
Commercially available serotonin-type 3 (5-HT3) receptor antagonists (ondansetron, granisetron, and tropisetron) have shown no clinically significant adverse effects on the cardiovascular system. In the dose-ranging evaluation of dolasetron, computer-generated ECGs revealed clinically asymptomatic prolongations of ECG intervals. We performed a clinical trial in which the possible changes in ECG intervals following a single 3-mg i.v. injection of granisetron and an injection of either doxorubicin or epirubicin were registered using computerized ECG analysis in cancer patients. A total of 30 patients who were designated to receive 3 mg granisetron i. v. for the prophylaxis of emesis induced by doxorubicin or epirubicin were entered into the study. Computer-generated ECG tracings were obtained before treatment, following the injection of 3 mg granisetron, and immediately after doxorubicin or epirubicin injection. The mean PR interval duration increased from 160 to 166 ms after granisetron infusion (P = 0.02). Doxorubicin and epirubicin did not potentiate this change. There was no statistically significant change in cardiac rhythm, QRS duration, or QTc intervals. The observed minor changes in the PR time following i. v. injection of granisetron do not seem to be of clinical relevance.
This is a preview of subscription content, log in via an institution to check access.
References
Fleming GF, Vokes EE, McEvilly JM, et al. (1991) Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin induced emesis. Cancer Chemother Pharmacol 28: 226–227
Gralla RJ (1993) Adverse effects of treatment. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 4th edn. Lippincott, Philadelphia pp 2341–2343
Hesketh PJ, Harvey WH, Harker WG, et al (1994) A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 12: 596–600
Kris MG, Grunberg SM, Gralla RJ, et al (1994) Dose-ranging evaluation of serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 12: 1045–1049
Menard O, Martinet Y, Lamy P (1991) Cisplatin-induced atrial fibrillation. J Clin Oncol 9: 192–193
Rezkalla S, Kloner RA, Ensley J, et al (1989) Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 7: 509–514
Roila F, De Angelis V, Del Favero A, et al (1994) Antiemetic efficacy and tolerability of dexamethasone (DEX) vs granisetron (GRAN) vs GRAN+DEX in patients (Pts) submitted to moderately emetogenic antineoplastic agents (MEAA): a double-blind randomized multicentre study (abstract 994). Proceedings, 19th congress of the European Society for Medical Oncology, Lisbon, p 994
Rowinsky EK, McGuire WP, Guarniere T, et al (1991) Cardiac disturbances during the administration of Taxol. J Clin Oncol 9: 1704–1712
Smaldone L, Murphy W, Dombernowsky P, et al (1990) Antiemetic activity of batanopride (BMY-25801) in patients receiving cisplatin: a randomized double-blind parallel comparison of two doses (abstract). Proceedings, 17th congress of the European Society for Medical Oncology, Copenhagen, p 109
Upward JW, Arnold BD, Link C, et al (1990) The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist. Eur J Cancer 26 [Suppl 1]: 12–15
Wortman JE, Lucas VS, Schuster E, et al (1979) Sudden death during doxorubicin administration. Cancer 44: 1588–1591
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jantunen, I.T., Kataja, V.V., Muhonen, T.T. et al. Effects of granisetron with doxorubicin or epirubicin on ECG intervals. Cancer Chemother Pharmacol 37, 502–504 (1996). https://doi.org/10.1007/s002800050420
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s002800050420